TrialBritish journal of cancer2012

VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.

J L Kuiper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.